ライフサイエンスコーパス: dopamine receptor

1 says and inhibition of ligand binding to the dopamine receptor.

2 ion of GluN2A and GluN2B subunits and the D1 dopamine receptor.

3 ter in the case of beta(2)AR than M2R and D2 dopamine receptor.

4 ues in this region of the closely related D2 dopamine receptor.

5 to the mushroom bodies, via the D5-like DAMB dopamine receptor.

6 re-based campaign for new agonists of the D4 dopamine receptor.

7 that it was mediated by activation of D1/D5 dopamine receptors.

8 eptors: D1 and Invertebrate-specific D1-like dopamine receptors.

9 sal hippocampus despite the dense network of dopamine receptors.

10 ed preparations, suggesting spinally located dopamine receptors.

11 prepared from HEK293 cells expressing human dopamine receptors.

12 ium spiny neurons (MSNs) expressing D1 or D2 dopamine receptors.

13 CZ) function primarily by blocking D(2)-type dopamine receptors.

14 otics function primarily by blocking D2-type dopamine receptors.

15 axivity and high binding affinity toward the dopamine receptors.

16 function involves sensitization of striatal dopamine receptors.

17 in the regulation of forward locomotion via dopamine receptors.

18 s with varying affinity at sigma and D2-like dopamine receptors.

19 (M2R), beta(2)-adrenergic (beta(2)AR), or D2 dopamine receptors.

20 ighting the functional role of extrastriatal dopamine receptors.

21 ir predominant expression of either D1 or D2 dopamine receptors.

22 ts through mechanisms not supported by other dopamine receptors.

23 ty during risky decision-making and striatal dopamine receptors.

24 c mice to evaluate induction of DeltaFosB in dopamine receptor 1 (D1) enriched and dopamine receptor

25 ge homolog 4 (Drosophila) (DLG4, PSD-95) and dopamine receptor 1 (DRD1) within the postsynaptic densi

26 mouse nAc and were located preferentially in dopamine receptor 1 (DRD1)-positive MSNs.

27 gneto to delineate a causal role of striatal dopamine receptor 1 neurons in mediating reward behavior

28 atory subunit 1B(+) BLA pyramidal neurons to dopamine receptor 1(+) CeA neurons define a pathway for

29 dopamine-induced surface GluA1 expression in dopamine receptor 1-expressing medium spiny neurons.

30 e of Neuron, O'Connor et al. (2015) identify dopamine receptor 1-expressing neurons that project to t

31 ng c-Fos induction and excitatory input onto dopamine receptor-1 (D1) containing NAc medium spiny neu

32 The ghrelin receptor (GHSR1a) and dopamine receptor-1 (DRD1) are coexpressed in hippocampa

33 Finally, we identified dopamine receptor-1 expressing medium spiny neurons as k

34 p11 homeostasis in the NAc, particularly in dopamine receptor-1 expressing medium spiny neurons, may

35 P-expressing neurons in adult Area X express dopamine receptors 1A, 1B, and 2.

36 osB in dopamine receptor 1 (D1) enriched and dopamine receptor 2 (D2) enriched MSNs in ventral striat

37 us characterization of Slc6a15 as a striatal dopamine receptor 2 (D2)-neuron-enriched gene, we examin

38 emale, deletion animals overexpress mRNA for dopamine receptor 2 and adenosine receptor 2a in the str

39 Activation of dopamine receptor 2 long (D2L) switches the signaling of

40 hile R-spondin 2(+) BLA pyramidal neurons to dopamine receptor 2(+) CeA neurons define a pathway for

41 , we show that ELS-induced downregulation of dopamine receptor 3 (Drd3) signaling and its correspondi

42 tropin-releasing hormone receptor) and Drd4 (dopamine receptor 4).

43 The D3 dopamine receptor, a member of the Gi-coupled D2 family

44 ceptors in PFC.SIGNIFICANCE STATEMENT The D3 dopamine receptor, a member of the Gi-coupled D2 family

45 PIT approach may be useful for understanding dopamine receptor abnormalities in neuropsychiatric diso

46 The hypothesis that dopamine receptor activation enhances perceptual perform

47 hippocampal apoptosis as a result of type 2 dopamine receptor activation in response to vagal signal

48 Dopamine receptor activation is known to enhance both vi

49 direct link has not been established between dopamine receptor activation, NAc cue-evoked neuronal ac

50 of this cross-sensitization, potentially via dopamine receptor activation.

51 demonstrate that antagonism of serotonin and dopamine receptor activity can alter the way individuals

52 Dopamine receptor activity modulates the coupling of the

53 Previous work has found that dopamine receptor activity of healthy adults can modulat

54 acological manipulations of gap junction and dopamine receptor activity provide compelling evidence t

55 ectroretinogram b-wave from cones, whereas a dopamine receptor agonist can potentiate the cone-driven

56 ioural responses after challenge with the D2-dopamine receptor agonist quinpirole.

57 xaggerated in DRD mice in response to the D1-dopamine receptor agonist SKF 81297.

58 drenoreceptor antagonist, timolol, the D1/D5 dopamine receptor agonist, SKF38393, and the H2 histamin

59 e-blinded, placebo-controlled study with the dopamine receptor agonists cabergoline (a D2 agonist) an

60 Because dopamine receptor agonists differentially modulate these

61 As in mammals, application of dopamine receptor agonists differentially modulates the

62 sor l-DOPA (l-3,4-dihydroxyphenylalanine) or dopamine receptor agonists reduced the number of histami

63 Administration of D1- or D2-like dopamine receptor agonists to enhance dopamine signallin

64 ceptive neurons, the effects of dopamine and dopamine receptor agonists were tested on the capsaicin-

65 hallenged with l-dopa (levodopa) and various dopamine receptor agonists, and resulting rotational beh

66 jor health problems in diabetic patients, D1 dopamine receptor agonists, which are already in clinica

67 and surveys the prospects for developing new dopamine receptor allosteric drugs with SB269652 as the

68 omous in their expression of either D1 or D2 dopamine receptors, along with other receptors and neuro

69 We found previously that loss of D2-family dopamine receptors ameliorated tauopathy in multiple mod

70 d a novel G protein-biased agonist of the D2 dopamine receptor and identified structural features tha

71 veral G-protein-coupled receptors, including dopamine receptor and mu opioid receptor (MOR).

72 Thus, it can be speculated that a failure of dopamine receptor and transporter homoeostasis might und

73 Alterations of dopamine receptors and dopamine synthesis are seen in ag

74 -induced neurotoxicity, associations between dopamine receptors and gray-matter volume have been unex

75 in response to the prolonged blockade of D2 dopamine receptors and is necessary to reduce the expres

76 our finding of changes in gene expression of dopamine receptors and modulators after the onset of the

77 orders caused by intermittent stimulation of dopamine receptors and off-target effects, respectively.

78 The relationship between dopamine receptors and stimulant-enhanced flexibility wa

79 n FFS evaluation of interactions between the dopamine receptors and the Gbetagamma complex.

80 , adrenergic receptors, adenosine receptors, dopamine receptor, and sphingosine 1-phosphate receptor.

81 limbic cortex (PrLC) and involved a D(1)/(5) dopamine receptor- and phosphorylation-dependent interna

82 Although dopamine receptor antagonism has long been associated wi

83 As CBD's effects do not appear to depend on dopamine receptor antagonism, this agent may represent a

84 By administering the D2/D3 dopamine receptor antagonist [(11)C]raclopride at varyin

85 size DHCB and show that it displays moderate dopamine receptor antagonist activities.

86 Treatment of aged mutant mice with the dopamine receptor antagonist haloperidol precipitated mo

87 neous recording of neuronal firing and local dopamine receptor antagonist injection.

88 ion, was attenuated by pretreatment with the dopamine receptor antagonist, flupenthixol, into the cor

89 -accumbens core flupenthixol, a nonselective dopamine receptor antagonist, on context renewal.

90 oselective synthesis of (+)-sonepiprazole, a dopamine receptor antagonist.

91 ed" methamphetamine seeking, using selective dopamine receptor antagonists (SCH39166 or raclopride) a

92 Novel dopamine receptor antagonists aripiprazole and ecopipam

93 Although a variety of dopamine receptor antagonists blocked cocaine self-admin

94 ts, whereas administration of D1- or D2-like dopamine receptor antagonists to further reduce dopamine

95 Tardive dyskinesia results from exposure to dopamine receptor antagonists, such as typical and atypi

96 ion and depression-like symptoms, than other dopamine receptor antagonists.

97 nge alcohol drinking, and its sensitivity to dopamine receptor antagonists.

98 domisation was stratified by baseline use of dopamine receptor antagonists.

99 dopamine neuron stimulation and resistant to dopamine receptor antagonists.

100 Although D1 and D2 dopamine receptors are differentially expressed in the d

101 Dopamine receptors are implicated in the pathogenesis an

102 Here we demonstrate that dopamine receptors are present in sensory hair cells at

103 tor, a member of the Gi-coupled D2 family of dopamine receptors, are expressed throughout limbic circ

104 We identified the Drd3 dopamine receptor as a direct transcriptional target of

105 d by dopamine, and requires activation of D1-dopamine receptors, as well as NMDA receptors (NMDAR) an

106 ers are associated with deficits in striatal dopamine receptor availability, abnormalities in mesocor

107 D2 and D3 dopamine receptors belong to the largest family of cell

108 vided mixed evidence regarding central D2/D3 dopamine receptor binding and its relationship with obes

109 Although abnormal striatal dopamine receptor binding has been implicated in the pat

110 In addition, reduced dopamine receptor binding was detectable by in vivo imag

111 s partially sensitive to GIRK channel and D2 dopamine receptor block.

112 Dopamine receptor blockade did not prevent the MDPV-indu

113 groups showed dose-dependent sensitivity to dopamine receptor blockade.

114 age tests, neither group was affected by DLS dopamine receptor blockade.

115 s (NAc), and pharmacological blockade of NAc dopamine receptors blocked corticosterone-induced potent

116 intracerebroventricular raclopride (a type 2 dopamine receptor blocker) ameliorated this effect.

117 is a persistent movement disorder induced by dopamine receptor blockers, including antipsychotics.

118 concentrations of dopamine, with or without dopamine receptor blockers.

119 cerebroventricularly injected with selective dopamine-receptor blockers.

120 factor CCAAT/enhancer-binding protein and a dopamine receptor, both with a known function in memory

121 To better understand how loss of D2-family dopamine receptors can ameliorate tau toxicity, we scree

122 atal glutamatergic synapses and of D1 and D2 dopamine receptor clusters.

123 The D(1) dopamine receptor (D(1)R) has been proposed to form a he

124 osed to form a hetero-oligomer with the D(2) dopamine receptor (D(2)R), which in turn results in a co

125 iny neuron (MSN) subtypes, those enriched in dopamine receptor D1 (D1-MSN) versus D2 (D2-MSN).

126 k indicating that molecular sensitization to dopamine receptor D1 (D1R) stimulation is involved in dy

127 By functionally rewiring the human dopamine receptor D1 (DRD1) via the second messenger cyc

128 mpounds revealed that a selective agonist of dopamine receptor D1 (DRD1), A77636, inhibited prolifera

129 ck-out mice, concomitant reduction of Gad65, dopamine receptor D1 (Drd1), and substance P expression

130 ruption of LI was attenuated in mice lacking dopamine receptor D1 (Drd1-/-), suggesting that D1 may p

131 iny neuron (MSN) subtypes, those enriched in dopamine receptor D1 versus dopamine receptor D2, in rew

132 s expressed either in dopamine neurons or in dopamine receptor D1-containing neurons play an importan

133 n hippocampal pyramidal neurons and striatal dopamine receptor D1-expressing neurons of Plcg1-deficie

134 As a proof-of-concept, we generated D1-dopamine receptor (D1) BAC MORF mice that label about 1%

135 nocked out (KO) in neurons expressing the D1 dopamine receptor (D1-KO), but not mice where WAVE1 was

136 m spiny projection neurons expressing the D1 dopamine receptor (D1-MSNs) in the nucleus accumbens.

137 beta2-adrenergic receptor (beta2-AR) and D1 dopamine receptor (D1-R).

138 d amygdala innervation of MSNs expressing D1 dopamine receptors (D1-MSNs) relative to D2-MSNs.

139 ary glands is mediated through two different dopamine receptors, D1 and InvD1L, for different downstr

140 s involves autocrine dopamine activating two dopamine receptors: D1 and Invertebrate-specific D1-like

141 econd, rodents with focally disrupted MFC D1 dopamine receptor (D1DR) signaling had impaired interval

142 after repeated exposure to cocaine, D1-like dopamine receptor (D1DR) stimulation reverses plastic ch

143 tigate the functional interaction between D1 dopamine receptors (D1DR) and AMPARs in the NAc, and exp

144 D1 and D2 dopamine receptors (D1DRs and D2DRs) may contribute diff

145 licated medial frontal neurons expressing D1 dopamine receptors (D1DRs) in temporal processing.

146 us work indicated that activation of D1-like dopamine receptors (D1DRs) in the nucleus accumbens shel

147 receptor (mGluRI) activation, facilitates D1 dopamine receptor (D1R) expression, and ensures long-ter

148 n the striatum and, by doing so, promotes D1 dopamine receptor (D1R) expression.

149 The D1 dopamine receptor (D1R) is widely expressed in the kidne

150 ibosomal protein L10a driven by the D1 or D2 dopamine receptor (D1R, D2R) promoter, respectively.

151 ted by the differential actions of D1 and D2 dopamine receptors (D1R, D2R), the expression of which i

152 re suggested to exert behavioral effects via dopamine receptor D2 (D2).

153 The human dopamine receptor D2 (DRD2) has been implicated in the p

154 tein subunit alphai2 mediates the effects of dopamine receptor D2 (DRD2) on cyclic adenosine monophos

155 cholinergic muscarinic receptor 4 [Chrm4)], dopamine receptor D2 [Drd2], and transcription factor 4

156 An increased formation of dopamine receptor D2 homodimers has been suggested to be

157 The rs1076560 polymorphism of DRD2 (encoding dopamine receptor D2) is associated with alternative spl

158 clear whether any of these genes, other than dopamine receptor D2, are immediately relevant to antips

159 hose enriched in dopamine receptor D1 versus dopamine receptor D2, in reward and reinforcement leadin

160 triatopallidal projection neurons expressing dopamine receptor D2.

161 The D2 dopamine receptor (D2 DAR) is one of the most validated

162 was knocked out in neurons expressing the D2 dopamine receptor (D2-KO), exhibited a significant decre

163 the majority of plasma membrane-expressed D2 dopamine receptor (D2R) is microcompartmentalized within

164 ychotic treatments, commonly antagonizing D2 dopamine receptors (D2Rs), on cognitive deficits and mem

165 Importantly, altered expression of dopamine receptor D3 (D3R) in PBLs from PD patients has

166 Dopamine receptor D3 (DRD3) expressed on CD4(+) T cells

167 n is mediated primarily by activation of the dopamine receptor D3 subtype (DRD3), even though both DR

168 test the hypothesis that the variant of the dopamine receptor D4 (DRD4) gene (VNTR in exon 3), which

169 hat sub-threshold fear conditioning leads to dopamine receptor D4-dependent long-term depression (LTD

170 Dopamine receptors (DARs) are of particular interest for

171 aling type 4 (RGS4) activity, and blocked D1 dopamine receptor dependent long-term potentiation (LTP)

172 lume signals in striatal target regions in a dopamine receptor-dependent manner.

173 This study investigated the dynamics of dopamine receptor desensitization and internalization, t

174 Additional loss of D2-family dopamine receptors did not synergize with bas-1 suppress

175 nnel in dopaminergic neurons and the D2-like dopamine receptor DOP-3.

176 ls innate immune responses through a D1-like dopamine receptor, DOP-4, in Caenorhabditis elegans.

177 lso show that PDE4D9 is increased by D1-type dopamine receptor dopaminergic stimulation.

178 Dopamine receptor DopR mediates the unconditioned stimul

179 D offspring was associated with up-regulated dopamine receptor (DRD)-1 and -2 in the nucleus accumben

180 PNs during synaptogenesis and in response to dopamine receptor Drd1 activation.

181 We demonstrate that D1 dopamine receptor (Drd1) signaling within the SCN is nec

182 psin2 in Rgs9-2-expressing neurons, or in D1 dopamine receptor (Drd1)-enriched medium spiny neurons,

183 Here, we report a D1-like dopamine receptor (DRD1)-mediated long-term potentiation

184 ated genes showed altered expression, as did dopamine receptors Drd1a and Drd2 (both downregulated),

185 g gene Dgcr8 results in the elevation of the dopamine receptor Drd2 in the auditory thalamus, an abno

186 morphine tolerance, whereas activation of D2 dopamine receptor (Drd2)-enriched neurons does not signi

187 ated by antipsychotic agents that inhibit D2 dopamine receptors (Drd2s).

188 ances and pharmacologically targeting the D3 dopamine receptor (DRD3) is therefore of significant cli

189 lts were obtained for the 9-6 haplotype, the dopamine receptor DRD4 48 bp VNTR, and the enzyme COMT S

190 s, serotonin receptor 2A (5HTR2A) and the D4 dopamine receptor (DRD4), in DENV infection.

191 However, the role of extrastriatal dopamine receptors (DRs) in BG information processing is

192 pression of G(qalpha) with the D(1) and D(2) dopamine receptors enhanced the dopamine-stimulated calc

193 at striatal neurons expressing the D1 and D2 dopamine receptors exert opposing brain-wide influences.

194 D2-dopamine receptors exhibited a change in the valence in

195 striatal region innervated, and the type of dopamine receptor expressed by striatal neurons.

196 pe and D2-type MSNs-based on the predominant dopamine receptor expressed.

197 fically impeding synaptic inhibition onto D1-dopamine receptor-expressing but not D2-dopamine recepto

198 and likely increased silent synapses onto D1 dopamine receptor-expressing direct pathway MSNs in both

199 nt synapses onto NAc shell, but not core, D2 dopamine receptor-expressing indirect pathway MSNs.

200 Distinct populations of D1- and D2-dopamine receptor-expressing medium spiny neurons (D1-/D

201 ctivity-dependent gene Fos in both D1 and D2 dopamine receptor-expressing medium spiny neurons (MSNs)

202 sis revealed that RIIbeta reexpression in D2 dopamine receptor-expressing medium spiny neurons correc

203 o D1-dopamine receptor-expressing but not D2-dopamine receptor-expressing medium spiny neurons.

204 Here, we demonstrate a role for D1-type dopamine receptor-expressing neurons in the medial prefr

205 It is widely accepted that D1 dopamine receptor-expressing striatal neurons convey the

206 ic afferents to the striatum; and one of two dopamine-receptor-expressing efferent pathways of the st

207 frequency bands, we compared the D1- and D2-dopamine-receptor-expressing striatal medium spiny neuro

208 tein, NPAS2, in the NAc in the regulation of dopamine receptor expression and drug reward.

209 coincides with a significant increase in D1 dopamine receptor expression compared to juvenile rats i

210 MSNs can be divided by dopamine receptor expression into D1-class and D2-class

211 Changes in postsynaptic dopamine receptor expression matched changes in presynap

212 Striatal dopamine receptor expression was diminished significantl

213 all impaired dopamine-facilitated LTP or D1-dopamine receptor-facilitated LTP.

214 vealing a pathway by which drugs that target dopamine receptors for the treatment of neuropsychiatric

215 Depleting Rab23 prevents dopamine receptors from accessing the ciliary membrane.

216 Pharmacological enhancement of prefrontal D1 dopamine receptor function remains a promising therapeut

217 repeated cocaine treatment causes loss of D2 dopamine receptor functional responses via interaction w

218 R5 messenger RNA under the control of the D1 dopamine receptor gene promoter (mGluR5(KD-D1)) were tes

219 into a single signaling pathway: Dopamine--> Dopamine Receptor--> Scribble--> Rac--> Cofilin.

220 Drugs acting at D3 dopamine receptors have been suggested as medications fo

221 , we determined crystal structures of the D4 dopamine receptor in its inactive state bound to the ant

222 ich dopamine exerts its action via D1 and D2 dopamine receptors in a concentration-dependent manner.

223 opamine-targeting drugs and brain imaging of dopamine receptors in patients with mental illnesses.

224 context renewal was blocked by antagonism of dopamine receptors in the accumbens core.

225 e surface endothelium or lysoganglioside and dopamine receptors in the brain.

226 level, transient formation of homodimers of dopamine receptors in the membrane of stably transfected

227 red by cocaine and consequent stimulation of dopamine receptors (including D1 and D2) are associated

228 Activation of dopamine receptors increased the gain of synaptic transm

229 neurons release dopamine, activation of the dopamine receptors increases the activity of these mecha

230 t is responsible for A(2A) adenosine or D(1) dopamine receptor-induced neuro-protective response.

231 Activation of beta-adrenergic and D1/D5-dopamine receptors induces Ser1166 phosphorylation.

232 Despite evidence suggesting that midbrain dopamine receptors influence amphetamine-induced dopamin

233 e describe the invertebrate-specific D1-like dopamine receptor (InvD1L), which is highly expressed in

234 tor, a member of the Gi-coupled D2 family of dopamine receptors, is expressed throughout limbic circu

235 sing selective pharmacological compounds and dopamine receptor knockout (KO) mice, we show that DHCB

236 Increased DAT and D1 dopamine receptor levels appear to be responsible for th

237 as associated with the relative somatostatin/dopamine-receptors levels, especially sst5 and sst5TMD4.

238 athways might tightly interact downstream to dopamine receptors, likely resulting over time to increa

239 reduced, suggesting that activation of D1/D5 dopamine receptors may be preferentially linked to CaMKI

240 f STN-SNr synapses through an NMDAR-and D1/5 dopamine receptor-mediated endocytosis of synaptic AMPA

241 , decreased dopamine release, and smaller D2 dopamine receptor-mediated outward currents.

242 vestigated the presence of GlyRs in accumbal dopamine receptor medium spiny neurons (MSNs) of C57BL/6

243 380,000+ small-molecule library for novel D2 dopamine receptor modulators using a calcium mobilizatio

244 he negative modulator SB269652 and D2 and D3 dopamine receptor monomers and dimers, and surveys the p

245 lateral striatum and critically implicate D1-dopamine receptor, NMDAR, Cdk5, and CaMKII in cortico-st

246 lative fMRI measurements reflect basal D2/D3 dopamine receptor occupancy.

247 amine from melanocytes activates the D1-like dopamine receptor on primary sensory neurons.

248 ttenuated by coadministration of either a D1 dopamine receptor or NMDA glutamate receptor antagonist.

249 c appendage led to a series of high-affinity dopamine receptor partial agonists.

250 irst time demonstrate that stimulation of D1 dopamine receptors present in dermal fibroblasts restore

251 individuals with changes in available D2/D3 dopamine receptors (presumably due to intrasynaptic dopa

252 e dopaminergic transmission through blocking dopamine receptors, primarily DRD2.

253 Here, we combine dopamine receptor reporter lines, anatomical tracing tec

254 protein-coupled receptors (GPCRs), including dopamine receptors, represent a group of important pharm

255 evolutionary coupling potential derived from dopamine receptor sequences rather than with broader set

256 ase via D2-dependent synaptic plasticity and dopamine-receptor signal transduction.

257 imary screen were examined for orthogonal D2 dopamine receptor signaling activities including cAMP mo

258 ocial behavior, which was mediated by type 1 dopamine receptor signaling downstream in the NAc.

259 Here we report that stimulation of dopamine receptor signaling in vivo with systemic admini

260 In response to D1-dopamine-receptor signaling that is induced by drug admi

261 ate- and GABA-receptor signaling, and not on dopamine-receptor signaling.

262 Conversely, inhibiting striatal dopamine receptor signalling during glucose intake in sw

263 Ventral striatum- or D1 dopamine receptor-specific conditional knockout of Cdk5,

264 In the current study, we use dopamine receptor-specific pharmacology and multivoxel p

265 neuronal activity in the VTA and associated dopamine receptor stimulation is necessary for the synap

266 )-dependent mechanisms through adrenergic or dopamine receptor stimulation, and by several cAMP-indep

267 To illuminate dopamine receptor structure, function, and ligand recogn

268 ptor subtype 4 (M4) to oppose cAMP-dependent dopamine receptor subtype 1 (D1) signaling in presynapti

269 pressing tdTomato driven by the promoter for dopamine receptor subtype 1 (D1).

270 Triple transfections of the dopamine receptor subtype and Gbeta and Ggamma subunits,

271 investigated activities at two off-targets: dopamine receptor subtype D2 and endocannabinoid recepto

272 human fatty acid amide hydrolase (FAAH) and dopamine receptor subtype D3 (D3R).

273 en gray-matter thickness and BPnd for either dopamine receptor subtype in the control group.

274 previous studies neither isolated a role of dopamine receptor subtype nor identified the site of its

275 tigated the dynamic interactions between the dopamine receptor subtypes and their G-proteins using tw

276 ed higher affinity for D4, relative to other dopamine receptor subtypes, and that this activity might

277 arious types of mPFC neurons express several dopamine receptor subtypes, previous studies neither iso

278 le is known about the influence of different dopamine receptor systems on the subprocesses occurring

279 mmunication with target neurons via a set of dopamine receptors that control behavior associated with

280 Dopamine receptors thus reveal a previously unrecognized

281 at large mushroom spines of MSNs expressing dopamine receptor type 1 (D1-MSNs).

282 ted in the etiology of SZ and coding for the dopamine receptor type 2 (D2).

283 larger synaptic responses in MSNs expressing dopamine receptor type 2 (D2-MSNs).

284 s and alpha2A-adrenergic receptor, GABAB, or dopamine receptor type 2 receptors did not reveal any in

285 e early stages of Huntington's disease, when dopamine receptor type 2-expressing striatal medium spin

286 BAB, cannabinoid receptor type 1 (CB1R), and dopamine receptor type 2.

287 This activity occurred within dopamine receptor type-2 (D2R)-expressing cells in the n

288 pending on spike timing, dopamine level, and dopamine receptor type.

289 release, cell firing, and identification of dopamine receptor type.

290 : neurotransmitter release, cell firing, and dopamine-receptor type.

291 dative stress and altered mRNA expression of dopamine receptors, tyrosine hydroxylase, and dopamine t

292 of leptin expression, glial activation, and dopamine receptor upregulation in the nucleus accumbens

293 This action of D1 dopamine receptors was mediated through the protein kina

294 nteract with the orthosteric binding site of dopamine receptors, was actually a negative allosteric m

295 Song reinforcement diminished when dopamine receptors were blocked.

296 Further, D1-dopamine receptors were supersensitive; adenylate cyclas

297 a regulator of the membrane availability of dopamine receptors, were assessed in the experimental mo

298 ctional design can also be found at level of dopamine receptors, where augmenting D1 and abating D2 r

299 leased dopamine inhibits CINs through type 2 dopamine receptors, while another unidentified transmitt

300 To better understand the association of dopamine receptors with SCZ, we studied the expression o